Evidence map›Paper›PMID 37149673›Full record

ArticleBone marrow transplantation2023

Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT.

Jan Styczynski, Gloria Tridello, Linda Koster, Nina Knelange, Lotus Wendel, Anja van Biezen, Steffie van der Werf, Malgorzata Mikulska, Lidia Gil, Catherine Cordonnier and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Identification ofFrontiers in immunology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Jan StyczynskiDepartment of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Torun, Bydgoszcz, Poland. jstyczynski@cm.umk.pl.ORCID 0000-0002-3158-119X
Gloria TridelloPediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Linda KosterEBMT Leiden Study Unit, Leiden, The Netherlands.
Nina KnelangeEBMT Leiden Study Unit, Leiden, The Netherlands.
Lotus WendelEBMT Leiden Study Unit, Leiden, The Netherlands.
Anja van BiezenEBMT Leiden Study Unit, Leiden, The Netherlands.
Steffie van der WerfEBMT Leiden Study Unit, Leiden, The Netherlands.
Malgorzata MikulskaDivision of Infectious Diseases, University of Genoa (DISSAL) and Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0002-5535-4602
Lidia GilDepartment of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Catherine CordonnierHôpital Henri Mondor, Assistance Publique-Hopitaux de Paris (AP-HP) and Paris-Est-Créteil University, Creteil, France.
Per LjungmanDeptartment of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-8281-3245
Diana AverbuchFaculty of Medicine, Hebrew University of Jerusalem, Pediatric Infectious Diseases, Hadassah Medical Center, Jerusalem, Israel.
Simone CesaroPediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.ORCID 0000-0002-8698-9547
Helen BaldomeroEBMT Activity Survey Office, Hematology, Department of Medicine, University Hospital, Basel, Switzerland.ORCID 0000-0002-6554-483X
Christian ChabannonInstitut Paoli Calmettes Comprehensive Cancer Center and Inserm CBT-1409, Centre d'Investigations Cliniques en Biothérapies, Marseille, France.ORCID 0000-0002-3755-4889
Selim CorbaciogluDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.
Harry DolstraLaboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Bertram GlassKlinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
Raffaella GrecoUnit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.ORCID 0000-0002-6117-5328
Nicolaus KrögerDepartment of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.
Régis Peffault de LatourBMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.
Mohamad MohtyDepartment of Hematology, Hospital Saint Antoine, Sorbonne University, INSERM UMRs938, Paris, France.ORCID 0000-0002-7264-808X
Benedicte NevenPediatric Immune-Hematology Unit, Necker Children Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
Zinaida PericSchool of Medicine, University of Zagreb, University Hospital Center Zagreb, Zagreb, Croatia.ORCID 0000-0001-9458-8025
John A SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Anna SuredaClinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.
Ibrahim Yakoub-AghaCHU de Lille, Université de Lille, INSERM U1286, Infinite, Lille, France.ORCID 0000-0003-4524-8782
Rafael de la CamaraHematology Department, Hospital de la Princesa, Madrid, Spain.ORCID 0000-0002-8189-5779

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously analyzed trends in incidence and factors associated with lethal complications in ALL/AML/CML patients (causes of deaths; COD-1 study). The objective of this study was the analysis of incidence and specific causes of death after HCT, with focus on infectious deaths in two time periods, 1980-2001 (cohort-1) and 2002-2015 (cohort-2). All patients with HCT for lymphoma, plasma cell disorders, chronic leukemia (except CML), myelodysplastic/myeloproliferative disorders, registered in the EBMT-ProMISe-database were included (n = 232,618) (COD-2 study). Results were compared to those in the ALL/AML/CML COD-1 study. Mortality from bacterial, viral, fungal, and parasitic infections decreased in very early, early and intermediate phases. In the late phase, mortality from bacterial infections increased, while mortality from fungal, viral, or unknown infectious etiology did not change. This pattern was similar for allo- and auto-HCT in COD-1 and COD-2 studies, with a distinct and constant lower incidence of all types of infections at all phases, after auto-HCT. In conclusion, infections were the main cause of death before day +100, followed by relapse. Mortality from infectious deaths significantly decreased, except late phase. Post-transplant mortality has significantly decreased in all phases, from all causes after auto-HCT; it has decreased in all phases after allo-HCT except late phase.

Indexed as

Communicable DiseasesHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteLymphomaCause of DeathChronic DiseaseHumansRetrospective Studies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.